Search results for "Receptor"

Endometrial Adenocarcinoma in Syrian Hamsters Treated with Diethylstilbestrol, Tamoxifen and N-Ethyl-Nitrosourea

2006

The synthetic estrogen diethylstilbestrol (DES) causes marked abnormalities in the female hamster genital tract, after either prenatal or postnatal exposure, leading to endometrial hyperplasia and carcinoma. Acting as an initiating event, DES altering uterine development may facilitate the abnormal response of promoting agents. Tamoxifen (TAM) is an antiestrogen that competes for central and peripheral estrogen receptor (ERα). TAM exerts agonistic effects on E-dependent endometrial proliferation. N-ethyl-N-nitrosourea (ENU), a potent mutagenic agent, induces tumors in a variety of organs, predominantly in the peripheral nervous system. To test whether ENU and TAM treatment in a model of hyp…

Serotonin–dopamine interaction: an overview

2008

Central serotonergic and dopaminergic systems play a critical role in the regulation of normal and abnormal behaviours. Moreover, recent evidence suggests that the dysfunction of dopamine (DA) and serotonin (5-hydroxytriptamine, 5-HT) neurotransmission might underlie the pathophysiology of neuropsychiatric disorders, including depression, schizophrenia, attention deficit hyperactivity disorders, drug abuse, Gilles de la Tourette's syndrome and Parkinson's disease.

Functional relevance of soluble TNF-alpha, transmembrane TNF-alpha and TNF-signal transduction in gastrointestinal diseases with special reference to…

2002

As a result of extensive clinical and basic research, the pivotal role of tumour necrosis factor (TNF) in the pathogenesis of chronic inflammatory diseases such as inflammatory bowel disease (IBD) has now generally been acknowledged. This has led to promising clinically effective anti-TNF-strategies. Of note, there is more and more evidence that TNF seems to play a key role in other gastrointestinal diseases including Helicobacter pylori infection, pancreatitis, viral hepatitis and toxic liver damage, too. The action of TNF at the cellular level is mediated by two cell surface receptors, TNF-R1 (p60) and TNF-R2 (p80). The function of these receptors and the downstream intracellular signal t…

New glucocorticoids. Mechanisms of immunological activity at the cellular level and in the clinical setting.

1990

Glutamate Enhances Brain Damage from Ischemia and Trauma

1997

The amino acid glutamate is a model agent to demonstrate the significance of neurotoxic mediator compounds in secondary brain damage from trauma, ischemia or other adverse conditions. Intensive research of the role of mediator compounds is clinically worthwile as more specific forms of treatment may emerge for the benefit of afflicted patients. In view of the great number of factors, cytokines, etc., which could play a role, it is mandatory that a mediator function in secondary brain damage is identified according to the stringent requirements established for that purpose. Glutamate has been shown — as is the case for only a few other agents — to meet all the criteria of a mediator of secon…

Neuron-Glial Interaction During Injury and Edema of the CNS

1994

During injury and ischemia of the CNS mediator compounds are released or activated which cause secondary swelling and damage of nerve cells. Such mediators are glutamate, acidosis, free fatty acids, or high extracellular potassium. Glial homeostatic mechanisms are activated to prevent the secondary injury from these mediators. The glial clearance mechanisms have been studied in detail using in vitro systems allowing for a close control of the glial environment. Current evidence suggests glial swelling to occur together with glutamate uptake or in response to extracellular acidosis. Glial swelling, therefore, is rather the result of homeostatic mechanisms than an indication of glial demise.

Erythropoietin: a new paradigm for neuroprotection.

2006

Chronic Therapy with Isosorbide-5-Mononitrate Causes Endothelial Dysfunction and Oxidative Stress – Improvement by Endothelin-Receptor Blocker (Bosen…

2012

Cellular Acetylcholine Receptor Expression in the Brain of Patients with Alzheimer’s and Parkinson’s Dementia

1995

Binding studies and receptor autoradiography reveal the overall changes of acetylcholine receptors (AChR) in Alzheimer’s and Parkinson’s dementia cortices.2,5 A detailed account of these changes requires a study of neurochemical phenotype of individual neurons as basic elements of networks constituting the substrate of cortical functions.4 Examples will be given for cell-type specific AChR localization in normal and diseased human cerebral cortex.

Modulators of Endogenous Neuroprotection: Estrogen, Corticotropin-releasing Hormone and Endocannabinoids

2005

Age-associated neurodegenerative disorders are among the most challenging problems of our aging society. Alzheimer’s disease is affecting people with increasing frequency, since there is a clear relationship between the incidence of this detrimental disorder and age. Other neurodegenerative disorders, including Parkinson’s disease, stroke and amyotrophic lateral sclerosis, are also frequently observed in our aging society. For most of these diseases, no causal therapy has yet been identified. Many of the treatments given to patients that are affected by these disorders have different side effects, and therefore the search is on to identify novel molecular approaches that may lead to a more …